Pargluva Effect: Bristol Foresees More Independent Scrutiny Of Trial Data

Greater availability of clinical trial data through online databases could lead to more independent reviews of study results akin to a published analysis of Pargluva data, Bristol-Myers Squibb U.S. Pharmaceuticals President Anthony Hooper speculated during a press meeting Nov. 18

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet